Talphera Inc. (TLPH)

[alexander77]

Roth capital: acrx target price $22

'Analysts at, Roth Capital Initiated Coverage on shares of AcelRx Pharmaceuticals, Inc (ACRX) with a Buy rating and a price target of $22, suggesting 113 percent upside.

“We believe Zalviso is a disruptive technology that will transform the way many hospitals treat patients with moderate-to-severe acute pain, primarily in the postoperative setting, by providing a solution demonstrated to be safer, more effective and easier to use than the standard-of-care (SoC), intravenous (IV) patient-controlled analgesia (PCA) with morphine” Roth Capital said in a note to clients

“We are highly confident (90% probability) in Zalviso’s FDA approval by its July 27 PDUFA date. This will be followed almost immediately by P&T applications leading to formulary adoptions beginning in 4Q14, and first commercial sales in 1Q15. Also, AcelRx has guided to a pivotal Phase III trial of ARX-04 by 4Q14.” it added

Shares of AcelRx Pharmaceuticals, Inc (ACRX) closed at $10.32 on Friday.'
http://www.theeconomicdaily.com/2014/04/14/roth-capital-initiates-coverage-on-acelrx-pharmaceuticals-at-buy/